Chronic Idiopathic Constipation (CIC) Treatment Market To Witness Strong Growth Due To Rise In Prevalence Of Chronic Constipation

 

Chronic Idiopathic Constipation (CIC) Treatment Market

Overview:

Chronic idiopathic constipation (CIC) is classified as one of the functional gastrointestinal disorders, meaning that testing does not identify an abnormality in the digestive system. Management of CIC includes patient education, dietary changes and laxatives as well as behavior modification. The primary goal of chronic idiopathic constipation treatment is to improve the bowel movement frequency, ease of passing stool and control the pain and abdominal discomfort from constipation.

Market Dynamics:

The growing number of old age population across the globe is expected to propel growth of the global chronic idiopathic constipation (CIC) treatment market during the forecast period. Old age population is highly susceptible to suffering from CIC, as they use analgesics such as hydromorphone, morphine, codeine like prescription for chronic pain. This in turn affects their digestive system, due to which they are likely to suffer from CIC. Thus, this factor is projected to support growth of the market. For instance, as per the World Bank data, the geriatric population increased from 9.102% in 2019 to 9.321% in 2020, which is 723,184,486.

However, the decline in healthcare expenditure in some of the developing countries is anticipated to hinder growth of the global chronic idiopathic constipation (CIC) treatment market during the forecast period.

Impact of COVID-19:

The outbreak of the pandemic affected more than 200 countries across the world, and as a result the number of patient visits reduced everywhere. Moreover, the demand for constipation treatment also declined during the pandemic, which adversely affected growth of the chronic idiopathic constipation (CIC) treatment market. However, in some of the COVID-19 infection cases, the need for constipation treatment was emerging. Thus, the outbreak of COVID-19 and subsequent symptoms of irritable bowel syndrome or constipation are likely to drive growth of the market in the near future.

Key Takeaways:

·         The global chronic idiopathic constipation (CIC) treatment market is anticipated to grow with a CAGR of 7.0% during the forecast period, due to rise in cases of chronic constipation health disorders. For instance, as per the National Center for Biotechnology Information, the average prevalence of constipation among adults is estimated as 16% across the world, and 33.5% of prevalence was among adults aged 60 to 110 years.

·         Among regions, North America is expected to show significant growth in the global chronic idiopathic constipation (CIC) treatment market during the forecast period, owing to growing cases of chronic constipation in the region, and rise in investment in healthcare sector.

·         Key players functioning in the global chronic idiopathic constipation (CIC) treatment market are Boehringer Ingelheim GmbH, Takeda Pharmaceutical Company Ltd., Janssen Pharmaceutical Company, Ironwood Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Salix Pharmaceuticals, Inc., Pfizer Inc., Abbott Laboratories, Valeant Pharmaceuticals International Inc., AstraZeneca Plc, Bayer AG, Cosmo Pharmaceuticals NV, and Sanofi S.A.